This site is intended only for all Healthcare Professionals residing in South Africa
XELJANZ® (tofacitinib) contains lactose. Patients with hereditary conditions of galactose intolerance e. g. galactosaemia, Lapp lactase deficiency or glucose-galactose malabsorption should not take XELJANZ® (tofacitinib). XELJANZ® (tofacitinib) may have an effect on the glycaemic control of patients with diabetes mellitus.1
Copyright ©2023 Pfizer South Africa All rights reserved.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.co.za.
This website is brought to you by Pfizer South Africa
Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).
Copyright © 2023. Pfizer Laboratories (Pty) Ltd. All rights reserved
These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.
I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to Pfizer.co.za where you will be able to access reference information on Pfizer's prescription medicines.